Naperville, IL -- (SBWIRE) -- 03/12/2015 -- Reportstack, provider of premium market research reports announces the addition of Type 2 Diabetes - Pipeline Review, H1 2015 market report to its offering.
Type 2 Diabetes - Pipeline Review, H1 2015
Type 2 Diabetes - Pipeline Review, H1 2015, provides an overview of the Type 2 Diabetess therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Type 2 Diabetes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetes and special features on late-stage and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- The report provides a snapshot of the global therapeutic landscape of Type 2 Diabetes
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Type 2 Diabetes and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Type 2 Diabetes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Type 2 Diabetes pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Type 2 Diabetes
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Addex Therapeutics Ltd
Advinus Therapeutics Ltd.
Aegis Therapeutics, LLC
Alize Pharma SAS
AlphaMab Co., Ltd
Anchor Therapeutics, Inc.
Arena Pharmaceuticals, Inc.
Arisaph Pharmaceuticals, Inc.
Array BioPharma Inc.
Arrien Pharmaceuticals, LLC
Artery Therapeutics, Inc.
Astellas Pharma Inc.
AUS Bio Limited
Avaxia Biologics, Inc.
BioRestorative Therapies, Inc.
Boehringer Ingelheim GmbH
Boston Therapeutics, Inc.
Braasch Biotech LLC
Bridge Bioresearch Plc
Bristol-Myers Squibb Company
C4X Discovery Ltd
Cardax Pharmaceuticals, Inc.
Carlina Technologies SAS
Carmot Therapeutics, Inc.
Celon Pharma Sp. z o.o.
Chipscreen Biosciences Ltd
Chong Kun Dang Pharmaceutical Corp.
CJ CheilJedang Corp.
Connexios Life Sciences Pvt. Ltd.
CTI BioPharma Corp.
CymaBay Therapeutics, Inc.
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
Debiopharm International S.A.
Diasome Pharmaceuticals, Inc.
Dong-A Socio Group
Eisai Co., Ltd.
Elcelyx Therapeutics, Inc.
Eli Lilly and Company
Enzo Biochem, Inc.
Esperion Therapeutics, Inc.
Extrawell Pharmaceutical Holdings Limited
F. Hoffmann-La Roche Ltd.
Flamel Technologies S.A.
Foresee Pharmaceuticals, LLC
Generex Biotechnology Corporation
Genovate Biotechnology Co., LTD.
Gilead Sciences, Inc.
Glucox Biotech AB
GW Pharmaceuticals plc
Hadasit Medical Research Services & Development Ltd
Halozyme Therapeutics, Inc.
HanAll Biopharma Co., Ltd.
Hanmi Pharmaceuticals, Co. Ltd.
Harbor Therapeutics, Inc.
Heptares Therapeutics Ltd.
Hua Medicine Ltd.
Hyundai Pharmaceutical Co., Ltd.
Insusense Therapeutics ApS
Intarcia Therapeutics, Inc.
Integral Molecular, Inc.
Intercept Pharmaceuticals, Inc.
IPCA Laboratories Limited
Isis Pharmaceuticals, Inc.
Islet Sciences, Inc.
Japan Tobacco Inc.
Jenrin Discovery, Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Johnson & Johnson
Kadmon Corporation, LLC
Kareus Therapeutics, SA
Kissei Pharmaceutical Co., Ltd.
Lexicon Pharmaceuticals, Inc.
LG Life Sciences, Ltd.
Ligand Pharmaceuticals, Inc.
Longevity Biotech, Inc
Medesis Pharma S.A.
Medestea Research & Production S.p.A.
Merck & Co., Inc.
Metabolic Solutions Development Company, LLC
MI.TO. Technology S.r.L.
MidaSol Therapeutics LP
Mitsubishi Tanabe Pharma Corporation
Mochida Pharmaceutical Co., Ltd.
NeoPharm Co., Ltd.
Neurimmune Holding AG
Neurocrine Biosciences, Inc.
NGM Biopharmaceuticals, Inc.
Nordic Bioscience a/s
Novo Nordisk A/S
Noxxon Pharma AG
OPKO Health, Inc.
Oramed Pharmaceuticals, Inc.
Orbis Biosciences, Inc.
Orchid Chemicals & Pharmaceuticals Ltd
Panacea Biotec Limited
Paras Biopharmaceuticals Finland Oy
PhaseBio Pharmaceuticals, Inc.
Piramal Enterprises Limited
PlasmaTech Biopharmaceuticals, Inc.
Progen Pharmaceuticals Limited
Prometheon Pharma, LLC
ProMetic Life Sciences Inc.
Prothena Corporation plc
Ranbaxy Laboratories Limited
Reata Pharmaceuticals, Inc.
Red Glead Discovery AB
Regeneron Pharmaceuticals, Inc.
Regulus Therapeutics Inc.
Rhizen Pharmaceuticals SA
Rigel Pharmaceuticals, Inc.
Sanwa Kagaku Kenkyusho Co., Ltd.
SBI Pharmaceuticals Co., Ltd.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Shanghai Pharmaceutical Co., Ltd.
Shantani Proteome Analytics Pvt. Ltd.
Shionogi & Co., Ltd.
Shreya Life Sciences Pvt. Ltd.
SignPath Pharma Inc
Sihuan Pharmaceutical Holdings Group Ltd.
Sirona Biochem Corp
SK Chemicals Co., Ltd.
Starpharma Holdings Limited
Stelic Institute & Co.
Stempeutics Research Private Limited
Sumitomo Dainippon Pharma Co., Ltd.
Summit Corporation plc
Taisho Pharmaceutical Co., Ltd.
Takeda Pharmaceutical Company Limited
Teijin Pharma Limited
Teva Pharmaceutical Industries Limited
Thermalin Diabetes, LLC
Thetis Pharmaceuticals LLC
Toray Industries, Inc.
Torrent Pharmaceuticals Limited
Transgene Biotek Limited
Transition Therapeutics Inc.
TransTech Pharma, Inc.
TWi Pharmaceuticals, Inc.
Uni-Bio Science Group Ltd.
Upsher-Smith Laboratories, Inc.
Verva Pharmaceuticals Limited
Vicore Pharma AB
Vitae Pharmaceuticals, Inc.
X-BODY BioSciences, Inc.
XBiotech USA, Inc.
Xenetic Biosciences plc
Zealand Pharma A/S
Zydus Cadila Healthcare Limited
Complete report is available @